Introduction
============

Diabetes mellitus is defined as hyperglycemia resulting from impaired insulin secretion and peripheral insulin resistance ([@b1-mmr-19-05-3989]). Numerous types of diabetes mellitus exist, including type 1 diabetes (T1D), type 2 diabetes (T2D) and gestational diabetes mellitus ([@b1-mmr-19-05-3989]). T1D is an organ-specific disease that is characterized by the autoimmune destruction of pancreatic β cells leading to insulin deficiency ([@b2-mmr-19-05-3989]). In addition, islet infiltration by macrophages, lymphocytes, dendritic cells and natural killer (NK) cells is commonly observed in T1D, as is the overexpression of a number of immune system genes ([@b3-mmr-19-05-3989],[@b4-mmr-19-05-3989]).

T1D primarily affects children and young adults, and symptoms are typically more severe in children compared with adults. It has been reported that T1D accounts for 80--90% of diabetes in children and adolescents ([@b5-mmr-19-05-3989],[@b6-mmr-19-05-3989]). The onset of T1D is frequently sudden in children and adolescents, and a number of symptoms are exhibited, including enuresis, polyuria, polydipsia, polyphagia, extreme tiredness, blurred vision, sudden weight loss, lack of energy, slow-healing wounds and recurrent infections ([@b7-mmr-19-05-3989]), with severe dehydration and diabetic ketoacidosis. Patients with T1D are additionally at a higher risk of developing other autoimmune disorders, including vitiligo, Addison\'s disease, Graves\' disease, celiac sprue, Hashimoto\'s thyroiditis, myasthenia gravis, autoimmune hepatitis and pernicious anemia ([@b8-mmr-19-05-3989]). Furthermore, patients with T1D require long-term insulin treatment and have an increased risk of stroke, blindness, kidney failure and heart disease, all of which contribute to early patient mortality.

In order to reduce patient mortality, it is important to identify potential pathological genes that serve a role in the pathogenesis of T1D in children. The present study identified T1D-associated alterations in gene expression by integrating mRNA expression datasets from children with T1D from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in children with T1D were identified. Functional analysis was performed and a protein-protein interaction (PPI) network was constructed, followed by the transcription factor (TF)-target network construction. The expression of selected DEGs was further assessed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Electronic validation and diagnostic value analysis of the identified DEGs \[cytokine inducible SH2 containing protein (CISH), SR-related CTD associated factor 11 (SCAF11), estrogen receptor 1 (ESR1), Rho GTPase activating protein 25 (ARHGAP25), major histocompatibility complex, class II, DR β4 (HLA-DRB4) and interleukin 23 subunit α (IL23A)\] was performed in the GEO dataset. The results of the present study may improve diagnostic and treatment methods for children with T1D.

Materials and methods
=====================

### Datasets

In the present study, datasets from the GEO database (<http://www.ncbi.nlm.nih.gov/geo>) were searched using the key words 'diabetes mellitus, type 1' \[MeSH Terms\] OR 'type 1 diabetes' \[All Fields\] AND 'Homo sapiens' \[porgn\] AND 'gse' \[Filter\]. The study type may be described as 'expression profiling by array'. All selected datasets contained genome-wide expression data of the case group and/or normal group blood samples. In blood samples, monocytes were used for RNA sequencing analysis. A total of two datasets, GSE9006 and GSE33440, were included in the final analysis ([Table I](#tI-mmr-19-05-3989){ref-type="table"}).

### Analysis of DEGs

Raw expression data were downloaded and the limma (3.3.3) ([@b9-mmr-19-05-3989]) and metaMA packages (3.3.0) ([@b10-mmr-19-05-3989]) were used to identify the DEGs. The inverse normal method was used to combine P-values in metaMA. The threshold for DEGs was set at P\<0.05.

### Functional annotation analysis of DEGs

To elucidate the biological function and signaling pathways of DEGs, GeneCoDis3 (3.3.0) (<http://genecodis.cnb.csic.es/analysis>) software was used for Gene Ontology (GO; <http://www.geneontology.org/>) annotation and Kyoto Encyclopedia of Genes Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>) pathway enrichment. The thresholds of the GO function and KEGG pathways were P\<0.05.

### PPI network construction

Studying the interactions between proteins may aid elucidation of the underlying molecular mechanisms responsible for the pathogenesis of T1D in children. In order to gain insights into the interaction between proteins encoded by DEGs and other proteins, the predicted interactions between the top 100 proteins encoded by DEGs (50 upregulated and 50 downregulated) were retrieved from the BioGRID database (<http://thebiogrid.org>). The PPI network was subsequently visualized using Cytoscape Software (3.3.0) (<http://cytoscape.org>). Nodes in the PPI network denote proteins and edges denote interactions.

### Analysis of potential TFs that target DEGs

TFs serve a crucial role in the regulation of gene expression. The human genome TFs and motifs of genomic binding sites were downloaded from TRANSFAC (<http://genexplain.com/transfac>). The 2 kb sequences in the upstream promoter regions of the DEGs were downloaded from the University of California, Santa Cruz (Santa Cruz, CA, USA; <http://www.genome.ucsc.edu/cgi-bin/hgTables>) to determine potential TF target sites. Finally, the transcriptional regulatory network was visualized using Cytoscape software.

### RT-qPCR in vitro

A total of five children with T1D and five control individuals were recruited for the present study. All children were Han and the sex ratio was 6:4 (male:female). No additional auto-immune diseases were diagnosed in any subjects. Clinical data for T1D patients is presented in [Table II](#tII-mmr-19-05-3989){ref-type="table"}. Ethical approval was obtained from the Ethics Committee of Shandong Jining No. 1 People\'s Hospital (Jining, China) and informed written consent was obtained from all subjects.

Total RNA was extracted from 0.25 ml blood samples using the RNAliquid Reagent (Tiangen Biotech Co., Ltd., Beijing, China), according to the manufacturer\'s protocols. A total of 1 µg RNA was used with FastQuant Reverse Transcriptase (Tiangen Biotech Co., Ltd.) to synthesize cDNA for 5 min at 65°C followed by 60 min at 42°C and 5 min at 72°C. qPCR was performed in an ABI 7300 Real-time PCR system with SYBR^®^ Green PCR Master Mix (Tiangen Biotech Co., Ltd.). The thermocycling conditions were as follows: 15 min at 95°C followed by 40 cycles of 10 sec at 95°C, 30 sec at 55°C, 32 sec at 72°C, and 15 sec at 95°C, 60 sec at 60°C, 15 sec extension at 95°C. All reactions were performed in triplicate. GAPDH was used as the internal reference and relative gene expression was calculated as a fold-change. The sequences of reverse and forward primers for all of the genes analyzed were as follows: HNRNPD (forward: GAGGCGTGGGTTCTGCTTTAT, reverse: AGATCCCCACTGTTGCTGTTG); PRKAA1 (forward: TTGAAACCTGAAAATGTCCTGCT, reverse: GGTGAGCCACAACTTGTTCTT); ITGA4 (forward: AGCCCTAATGGAGAACCTTGT, reverse: CCAGTGGGGAGCTTATTTTCAT); TAP2 (forward: CACCTACACCATGTCTCGAATC, reverse: AGTTACTCATCAGGGTGGTATCC); GAPDH (forward: GGAGCGAGATCCCTCCAAAAT, reverse: GGCTGTTGTCATACTTCTCATGG). The experiment was repeated three times. The relative expression of genes was calculated using the 2^−ΔΔCq^ method ([@b11-mmr-19-05-3989]). The statistical analyses were performed using GraphPad Prism 2.0 (GraphPad Software, Inc., La Jolla, CA, USA).

### Electronic validation of DEGs and receiver operating characteristic (ROC) analysis

In order to determine the expression of DEGs, including CISH, SCAF11, ESR1, ARHGAP25, HLA-DRB4 and IL23A, the GEO dataset was subjected to electronic validation. The results are presented as box plots. The pROC package in R 2.0 (<http://web.expasy.org/pROC/>) ([@b12-mmr-19-05-3989]) was used for ROC analysis to assess the diagnostic value of these genes. The area under the curve (AUC) was calculated and the ROC curve was constructed.

Results
=======

### DEG analysis

Raw expression profiles were downloaded from the data portal of the GEO database. A total of 1,467 DEGs were identified, comprising 804 upregulated genes and 663 downregulated genes. The top 10 up- and downregulated DEGs are listed in [Table III](#tIII-mmr-19-05-3989){ref-type="table"} and a heat map of the top 100 DEGs is presented in [Fig. 1](#f1-mmr-19-05-3989){ref-type="fig"}.

### Functional and pathway enrichment analyses of DEGs

To investigate the biological functions of the identified DEGs in children with T1D, GO term and KEGG pathway enrichment analyses were performed. 'Signal transduction', 'regulation of transcription, DNA-dependent', 'positive regulation of transcription from RNA polymerase II promoter', 'blood coagulation' and 'apoptotic process' were the most significantly enriched biological processes. 'Protein binding', 'nucleotide binding' and 'metal ion binding' were the most markedly enriched molecular functions, and 'cytoplasm', 'nucleus' and 'cytosol' were the most significantly enriched cellular components. 'Cytokine-cytokine receptor interaction', 'lysosome' and 'tuberculosis' were the most significantly enriched KEGG signaling pathways. The top 15 GO terms of the DEGs are presented in [Figs. 2](#f2-mmr-19-05-3989){ref-type="fig"}--[4](#f4-mmr-19-05-3989){ref-type="fig"}. The top 15 KEGG enriched signaling pathways of the DEGs are presented in [Fig. 5](#f5-mmr-19-05-3989){ref-type="fig"}.

### PPI network

To assess the interactions between proteins encoded by the DEGs and other proteins, the PPI network was examined and visualized using Cytoscape software. PPI networks of the top 50 upregulated and top 50 downregulated DEGs are presented in [Fig. 6](#f6-mmr-19-05-3989){ref-type="fig"}. The network consists of 252 nodes and 260 edges. Red and cyan ellipses represent up- and downregulated proteins, respectively. Ellipses with blue or black borders represent proteins encoded by the top 100 upregulated and the top 100 downregulated DEGs, respectively. The top 13 proteins with a high degree of interaction with other proteins were heterogeneous nuclear ribonucleoprotein D (HNRNPD; degree=33), X-ray repair cross complementing 5 (degree=20), protein kinase AMP-activated catalytic subunit a1 (PRKAA1; degree=11), RNA polymerase II subunit C (degree=10), reticulon 4 (degree=9), replication protein A1 (degree=9), Y-box binding protein 3 (degree=8), DNA ligase 3 (degree=8), coatomer protein complex subunit α (degree=8), tripartite motif containing 25 (degree=8), chromosome 2 containing integrin subunit α4 (ITGA4; degree=8), ESR1 (degree=8) and mediator complex subunit 9 (degree=6).

### Establishment of TF-target genes regulatory network

In order to investigate the regulatory network of TF-target genes for children with T1D, TRANSFAC was utilized to obtain TFs for the top 10 upregulated or downregulated DEGs. A transcriptional regulatory networks consisting of 250 pairs of TF-genes involving 36 TFs was obtained ([Fig. 7](#f7-mmr-19-05-3989){ref-type="fig"}). Diamonds and ellipses represent TFs and genes, respectively. Red and cyan coloring represents up- and downregulation, respectively. In this network, the top 9 downstream genes covered by the majority of TFs were ARHGAP25 (degree=12), HNRNPD (degree=10), zinc finger protein 473 (degree=10), HLA-DRB4 (degree=10), IL23A (degree=9), protein phosphatase 2 regulatory subunit B\'ε (degree=9), acyloxyacyl hydrolase (degree=8), complement C3d receptor 2 (degree=7) and N-glycanase 1 (degree=7).

### RT-qPCR

In the present study, four candidate genes were selected for validation: HNRNPD, PRKAA1, ITGA4 and transporter 2, ATP binding cassette subfamily B member (TAP2; [Fig. 8](#f8-mmr-19-05-3989){ref-type="fig"}). The results demonstrated that HNRNPD (P=0.465), PRKAA1 (P=0.256), ITGA4 (P=0.236) and TAP2 (P=0.295) were downregulated, although these results were not statistically significant.

### Electronic validation of DEGs and ROC analysis

The results of electronic validation revealed that CISH, ESR1, ARHGAP25, HLA-DRB4 and IL23A were upregulated and SCAF11 was downregulated in T1D, which was consistent with the bioinformatics analysis. Expression box plots of these DEGs are presented in [Fig. 9](#f9-mmr-19-05-3989){ref-type="fig"}. Additionally, ROC curve analysis was performed and the AUC calculated to assess the discriminatory ability of these genes ([Fig. 10](#f10-mmr-19-05-3989){ref-type="fig"}). SCAF11 had the largest AUC. For children with T1D, the specificity and sensitivity of CISH were 58.3 and 93%, respectively; the specificity and sensitivity of SCAF11 were 87.5 and 79.1%, respectively; the specificity and sensitivity of ESR1 were 62.5 and 69.8%, respectively; the specificity and sensitivity of ARHGAP25 were 79.2 and 60.5%, respectively; the specificity and sensitivity of HLA-DRB4 were 62.5 and 83.7%, respectively; and the specificity and sensitivity of IL23A were 70.8 and 58.1%, respectively. In summary, CISH, SCAF11 and ARHGAP25 had a good diagnostic value for children with T1D as the AUC was \>0.7.

Discussion
==========

The present study identified that CISH and SCAF11 were the most up- and downregulated genes in children with T1D. The CIS/suppressors of cytokine signaling (SOCS) family serves an important role in various immunological processes ([@b13-mmr-19-05-3989]--[@b16-mmr-19-05-3989]). CISH, a member of the SOCS family, is expressed in every cell and is rapidly induced by a number of stimuli, including cytokines (erythropoietin, IL-2, IL-3 and IL-5), hormones, glucose, immune complexes and Toll-like receptor ligands ([@b17-mmr-19-05-3989]--[@b19-mmr-19-05-3989]). Another study suggested that CISH was a critical negative regulator of IL-15 signaling in NK cells and that CISH deletion enhanced anti-tumor immunity ([@b20-mmr-19-05-3989]). Decreased CISH expression in circulating peripheral blood mononuclear cells is associated with the severity of autoimmune diseases ([@b21-mmr-19-05-3989]). Recently, CISH has emerged as an important modulator of β-cell insulin desensitization following prolonged glucose exposure. It has been reported that the expression and DNA methylation of CISH alter in response to hyperglycemia ([@b22-mmr-19-05-3989]). Furthermore, the expression of CISH proteins is upregulated in islet cells from patients with T1D compared with healthy individuals ([@b23-mmr-19-05-3989]). In mouse models, CISH is also associated with the T2D phenotype ([@b24-mmr-19-05-3989]). SCAF11, also termed SFRS2IP, is a protein that is required for pre-mRNA splicing. Delunardo *et al* ([@b25-mmr-19-05-3989]) identified that SCAF11 was involved in Behcet\'s disease, which has certain features of autoimmunity. In the present study, the electronic validation of CISH and SCAF11 was consistent with the bioinformatics analysis. Importantly, CISH and SCAF11 had diagnostic value for children with T1D. The results suggested that CISH and SCAF11 may serve crucial roles in autoimmunity and may be associated with the pathology of T1D in children.

In the PPI network, a number of genes with a high degree of protein interactions, including HNRNPD, PRKAA1, ITGA4 and ESR1 were identified. HNRNPD, additionally termed AUF1, is known to serve roles in mRNA regulation and the stability of proteins in the inflammatory response and developmental processes ([@b26-mmr-19-05-3989]). It has been demonstrated that HNRNPD knockdown decreases glucose deprivation-induced apoptosis, whereas HNRNPD overexpression has the opposite effect ([@b27-mmr-19-05-3989]). The present study first identified that HNRNPD expression was downregulated in the blood of children with T1D. Furthermore, the results of the RT-qPCR validation were consistent with the bioinformatics analysis. The results further suggested that HNRNPD is associated with the progression of T1D in children.

In mammals, the PRKAA1 protein is one of the subunits of 5′-adenosine monophosphate-activated protein kinase, an important metabolic switch that governs glucose metabolism in response to alterations in intracellular energy levels in pancreatic β-cells ([@b28-mmr-19-05-3989]). PRKAA1 activation results in glucose transporter upregulation. It has been reported that PRKAA1 serves roles in gluconeogenesis and is important for glucose-stimulated insulin secretion from pancreatic β-cells ([@b29-mmr-19-05-3989],[@b30-mmr-19-05-3989]). It has also been reported that PRKAA1 expression is significantly decreased in islets in T2D ([@b31-mmr-19-05-3989]). To the best of the authors\' knowledge, the present study is the first to report that that PRKAA1 is downregulated in the blood of children with T1D. The results suggested that PRKAA1 may serve a vital role in the pancreatic β-cells of children with T1D.

Nalls *et al* ([@b32-mmr-19-05-3989]) reported that specific loci that regulate immune cell frequency on ITGA4 are associated with immune-mediated disorders. In addition, the rs1449263 polymorphism of ITGA4 has been studied in a number of autoimmune diseases ([@b33-mmr-19-05-3989]). It has been identified that the rs13010713 polymorphism of ITGA4 is present in T1D ([@b34-mmr-19-05-3989]). The present study identified that ITGA4 was downregulated in the blood of children with T1D. Notably, the results of RT-qPCR validated the expression of ITGA4. The present study provided additional evidence that ITGA4 serves important roles in the pathogenesis of T1D in children.

ESR1 is expressed by thymocytes, T cells, B lymphocytes, thymic epithelial cells and non-hematopoietic bone marrow cells, which serve roles in the functioning of the immune system ([@b35-mmr-19-05-3989]--[@b41-mmr-19-05-3989]). Ribas *et al* ([@b42-mmr-19-05-3989]) identified that ESR1 serves a key role in protecting against and reducing inflammation, in addition to a key role in glucose tolerance ([@b43-mmr-19-05-3989]). It is known that men with the ESR1 null mutation exhibit insulin resistance and impaired glucose tolerance ([@b44-mmr-19-05-3989]). It has also been demonstrated that ESR1 polymorphisms, including variants in the intron 1-intron 2 region, are positively associated with the T2D phenotype ([@b45-mmr-19-05-3989]). In addition, ESR1 is a DEG associated with islet function and the exocrine function of the pancreas in patients with T1D ([@b46-mmr-19-05-3989]). The present study identified that ESR1 was upregulated in the blood of children with T1D, which suggested that ESR1 is closely associated with the pathology of children with T1D.

The TF-target genes regulatory network for children with T1D was obtained and investigated. In this network, a number of high-degree target genes of TFs were identified, including ARHGAP25, HLA-DRB4 and IL23A. ARHGAP25, a GTPase-activating protein for Rac, is upregulated in alveolar rhabdomyosarcoma and is required for cell invasion ([@b47-mmr-19-05-3989]). It has been reported that ARHGAP25 is an immune gene ([@b48-mmr-19-05-3989]) and the rs6714065 and rs7605681 polymorphisms of ARHGAP25 have been identified in T2D ([@b49-mmr-19-05-3989]). In the present study, ARHGAP25 was upregulated in the blood of children with T1D. Notably, it was identified that ARHGAP25 had potential diagnostic value for children with T1D. This suggested that ARHGAP25 may serve an important role in the development of T1D in children.

HLA-DRB4, additionally termed DR4, is important to the adaptive immune system. Genetic variation in the HLA region is associated with diabetes risk ([@b50-mmr-19-05-3989]) and the HLA class II allele confers genetic susceptibility to T1D ([@b51-mmr-19-05-3989]). HLA-DRB4 is an immunity-associated gene that is differentially expressed in the intestine of insulin-resistant subjects ([@b52-mmr-19-05-3989]). It has been demonstrated that HLA-DRB4 confers susceptibility to T1D ([@b53-mmr-19-05-3989]). HLA-DRB4 is differentially expressed in the immune system and serves roles in antigen presentation in the islets of T1D patients ([@b46-mmr-19-05-3989]). It has been reported that HLA-DRB4 expression is significantly associated with childhood T1D ([@b54-mmr-19-05-3989]). The present study also identified an association between HLA-DRB4 and childhood T1D, which was in agreement with a previous study ([@b54-mmr-19-05-3989]).

IL23A is an autoimmune risk factor that belongs to the IL-12 heterodimeric cytokine family ([@b55-mmr-19-05-3989]). It has been reported that genetic variation in IL23A has an influence on T2D ([@b56-mmr-19-05-3989]) and that IL23A overexpression occurs in patients with T1D ([@b57-mmr-19-05-3989]). In the present study, IL23A expression was identified to be upregulated in the blood of patients with childhood T1D. The results suggested that IL23A may be involved in the pathogenesis of childhood T1D.

TAP2 is associated with a number of autoimmune diseases ([@b58-mmr-19-05-3989]). Vejbaesya *et al* ([@b59-mmr-19-05-3989]) reported that TAP2 served important roles in HLA-associated diseases and the immune response, including systemic lupus erythematosus and rheumatoid arthritis ([@b60-mmr-19-05-3989]). It has been reported that TAP2 is a risk factor for T1D ([@b61-mmr-19-05-3989]). The present study identified that TAP2 was downregulated in the blood of children with T1D. The results of RT-qPCR confirmed this, further suggesting that TAP2 served an important role in the development of childhood T1D.

In summary, the results of the present study revealed a number of genes that are differentially expressed in T1D, including CISH, SCAF11, HNRNPD, PRKAA1, ITGA4, ESR1, ARHGAP25, HLA-DRB4, IL23A and TAP2. These genes may serve a role in the pathogenesis of childhood T1D. CISH, SCAF11 and ARHGAP25 possess potential diagnostic value for children with T1D. However, there are a number of limitations to the present study. First, the sample size used for RT-qPCR was small; future studies may utilize a larger study group. Second, the biological functions of the identified genes were not investigated. In future, *in vivo* and *in vitro* experiments may be performed to verify the results of the present study.
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![Heat map of the top 100 DEGs. Hierarchal clustering was performed using the complete linkage method together with the Euclidean distance. Each row represents a DEG and each column represents a sample. The DEG clustering tree is presented on the right and the color scale illustrates the relative level of DEG expression: Red, below the reference channel; green, above the reference channel. DEGs, differentially expressed genes.](MMR-19-05-3989-g00){#f1-mmr-19-05-3989}

![Top 15 significantly enriched BPs of differentially expressed genes. The x-axis represents the number of differentially expressed genes. BP, biological process.](MMR-19-05-3989-g01){#f2-mmr-19-05-3989}

![Top 15 significantly enriched MFs of differentially expressed genes. The x-axis represents the number of differentially expressed genes. MFs, molecular function.](MMR-19-05-3989-g02){#f3-mmr-19-05-3989}

![Top 15 significantly enriched CCs of differentially expressed genes. The x-axis represents the number of differentially expressed genes. CC, cellular component.](MMR-19-05-3989-g03){#f4-mmr-19-05-3989}

![Top 15 significantly enriched Kyoto Encyclopedia of Genes and Genomes pathways of differentially expressed genes. The x-axis represents the number of differentially expressed genes.](MMR-19-05-3989-g04){#f5-mmr-19-05-3989}

![Protein-protein interaction networks of the top 100 DEGs. Red and cyan ellipses represent upregulated and downregulated genes, respectively. Ellipses with blue or black borders indicate proteins encoded by the top 100 upregulated and top 100 downregulated DEGs, respectively. DEGs, differentially expressed genes.](MMR-19-05-3989-g05){#f6-mmr-19-05-3989}

![TF networks of the top 20 DEGs. Diamonds and ellipses represent TFs and genes, respectively. Red indicates upregulation and cyan indicates downregulation. TF, transcription factor; DEGs, differentially expressed genes.](MMR-19-05-3989-g06){#f7-mmr-19-05-3989}

![Expression of selected genes in the blood of children with type 1 diabetes as assessed using the reverse transcription-quantitative polymerase chain reaction. ITGA4, integrin subunit α4; HNRNPD, heterogeneous nuclear ribonucleoprotein D; PRKAA1, protein kinase AMP-activated catalytic subunit α1; TAP2, transporter 2, ATP binding cassette subfamily B member.](MMR-19-05-3989-g07){#f8-mmr-19-05-3989}

![Box plots of selected differentially expressed genes. The x-axes illustrate control and case groups and the y-axes indicate the relative expression levels of the genes. CISH, cytokine inducible SH2 containing protein; SCAF11, SR-related CTD associated factor 11; ESR1, estrogen receptor 1; ARHGAP25, Rho GTPase activating protein 25; HLA-DRB4, major histocompatibility complex, class II, DR β4; IL23A, interleukin 23 subunit α.](MMR-19-05-3989-g08){#f9-mmr-19-05-3989}

![ROC curves of selected DEGs in children with type 1 diabetes compared with healthy controls. ROC curves were used to illustrate the diagnostic ability, sensitivity and specificity of the selected DEGs. The x-axes indicate specificity and the y-axes indicate sensitivity. ROC, receiver operating characteristic; DEGs, differentially expressed genes; CISH, cytokine inducible SH2 containing protein; SCAF11, SR-related CTD associated factor 11; ESR1, estrogen receptor 1; ARHGAP25, Rho GTPase activating protein 25; HLA-DRB4, major histocompatibility complex, class II, DR β4; IL23A, interleukin 23 subunit α.](MMR-19-05-3989-g09){#f10-mmr-19-05-3989}

###### 

GEO datasets.

  Author, year         GEO accession no.   Platform                                                 Samples (N:P)   (Refs.)
  -------------------- ------------------- -------------------------------------------------------- --------------- -------------------------
  Kaizer et al, 2007   GSE9006             GPL96 \[HG-U133A\] Affymetrix Human Genome U133A Array   24:81           ([@b62-mmr-19-05-3989])
  Irvine et al, 2012   GSE33440            GPL6947 Illumina HumanHT-12 V3.0 expression beadchip     6:16            ([@b63-mmr-19-05-3989])

GEO, gene expression omnibus; N, normal controls; P, patients with type 1 diabetes mellitus.

###### 

Clinical information on patients with childhood type 1 diabetes.

  A, Patients                                                                                                                                                                                                                            
  ----------------- --------- --------- --------------- ---------------------- ----------------------------------- --------- ------------------------------ ----------- --------- -------------------------------- ---------- ---------- ----------
    6               Male      19.1      Han             Yes                    No                                  7.2       23.1                           8.8         0.24      0.21                             Positive   Positive   Positive
    9               Female    21.9      Han             Yes                    No                                  7.6       21.9                           9.7         0.34      0.36                             Negative   Negative   Negative
  10                Male      19.8      Han             Yes                    No                                  8.1       23.9                           11.2        0.26      0.25                             Positive   Positive   Positive
    7               Female    20.3      Han             No                     No                                  9.2       24.8                           8.9         0.28      0.38                             Positive   Positive   Positive
    8               Male      19.9      Han             Yes                    No                                  7.3       22                             11.1        0.3       0.28                             Positive   Positive   Positive
                                                                                                                                                                                                                                         
  **B, Controls**                                                                                                                                                                                                                        
                                                                                                                                                                                                                                         
  **Age, years**    **Sex**   **BMI**   **Ethnicity**   **Diabetes history**   **Other chronic illness history**   **FBG**   **2 h postprandial glucose**   **HBA1C**   **FCP**   **2 h postprandial C-peptide**   **ICA**    **IAA**    **GADA**
                                                                                                                                                                                                                                         
    6               Male      16.8      Han             No                     No                                  N/A       N/A                            N/A         N/A       N/A                              N/A        N/A        N/A
    9               Female    17.1      Han             No                     No                                  N/A       N/A                            N/A         N/A       N/A                              N/A        N/A        N/A
  10                Male      16.9      Han             No                     No                                  N/A       N/A                            N/A         N/A       N/A                              N/A        N/A        N/A
    7               Female    17.6      Han             No                     No                                  N/A       N/A                            N/A         N/A       N/A                              N/A        N/A        N/A
    8               Male      18.1      Han             No                     No                                  N/A       N/A                            N/A         N/A       N/A                              N/A        N/A        N/A

BMI, body mass index; FBG, fasting blood glucose; HBA1C, glycosylated hemoglobin; FCP, fasting C-peptide; ICA, anti-islet cell antibody; IAA, anti-insulin antibody; GADA, anti-glutamate deoxygenase antibody.

###### 

Top 20 differentially expressed genes in children with type 1 diabetes.

  A, Upregulated genes                           
  ---------------------------- ----------------- -------------
  1154                         CISH              1.54×10-7
  3126                         HLA-DRB4          1.85×10-7
  25888                        ZNF473            4.29×10-7
  4860                         NP                7.90×10-7
  1380                         CR2               3.51×10-6
  28984                        C13orf15          5.07×10-6
  9938                         ARHGAP25          6.64×10-6
  2181                         ACSL3             1.22×10-5
  51561                        IL23A             1.51×10-5
  3097                         HIVEP2            1.91×10-5
                                                 
  **B, Downregulated genes**                     
                                                 
  **Gene ID**                  **Gene symbol**   **P-value**
                                                 
  9169                         SFRS2IP           4.40×10-8
  79932                        KIAA0319L         1.01×10-6
  3184                         HNRNPD            1.38×10-6
  55768                        NGLY1             3.77×10-6
  6891                         TAP2              1.66×10-5
  313                          AOAH              2.43×10-5
  7347                         UCHL3             2.61×10-5
  5529                         PPP2R5E           3.46×10-5
  2162                         F13A1             4.15×10-5
  85021                        REPS1             5.19×10-5
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